Related Experiment Video

Updated: Jul 7, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

Matrix metalloproteinase-3 genotypes influence recovery from hepatitis B virus infection

Jae Youn Cheong1, Sung Won Cho, Jung A Lee

  • 1Department of Gastroenterology, Genomic Research Center for Gastroenterology, Ajou University School of Medicine, Suwon, Korea.

Journal of Korean Medical Science
|February 28, 2008
PubMed

Insights

Single nucleotide polymorphisms (SNPs) in the matrix metalloproteinase-3 (MMP-3) gene may influence hepatitis B virus (HBV) persistence. The T allele at codon 96 of the MMP-3 gene was associated with a higher risk of persistent HBV infection.

Area of Science:

  • Immunogenetics
  • Hepatology
  • Virology

Background:

  • Hepatitis B virus (HBV) persistence is poorly understood, likely involving host immune factors.
  • Matrix metalloproteinases (MMPs) modulate inflammatory responses, suggesting a role in HBV infection outcomes.

Purpose of the Study:

  • To investigate the association between single nucleotide polymorphisms (SNPs) in MMP-3 and MMP-9 genes and susceptibility to persistent HBV infection.

Main Methods:

  • Genotyping of MMP-3 and MMP-9 gene SNPs in 489 Korean patients with HBV infection and 174 recovered healthy individuals.
  • Analysis of SNPs at MMP-3 codons 45 and 96, and MMP-9 codons 279, 607, and 668.
  • Statistical analysis using co-dominant models, adjusting for age and sex.

Main Results:

  • A significantly higher frequency of the T allele at the third position of codon 96 in the MMP-3 gene was observed in patients with persistent HBV infection (OR=1.242, p=0.049).

Conclusions:

  • The T allele at MMP-3 codon 96 may be a genetic factor contributing to the susceptibility of persistent hepatitis B virus infection.

More Related Videos

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA04:11

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA

Published on: December 15, 2023

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...